C. R. Bard

aid: cr-bard
name: C. R. Bard
kind: company
description: C. R. Bard, Inc. was an American multinational developer, manufacturer, and marketer of medical technologies
  in the fields of vascular, urology, oncology, and surgical specialties. Bard was founded in 1907 by Charles Russell Bard
  and was acquired by Becton, Dickinson and Company (BD) in December 2017 for approximately $24 billion. Bard's product lines
  now operate as part of BD's Interventional segment under the BD Bard brand. No public API or developer portal is published;
  integrations with hospital and provider systems are arranged through BD enterprise channels.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
specificationVersion: '0.23'
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/cr-bard.png
url: https://raw.githubusercontent.com/api-evangelist/cr-bard/refs/heads/main/apis.yml
x-api-posture: no-product-api
x-api-posture-basis: observed
x-api-posture-note: No public API or developer portal is published; integrations with hospital and provider systems are arranged
  through BD enterprise channels.
type: Index
access: 3rd-Party
position: Consuming
created: '2024-01-01'
modified: '2026-09-07'
tags:
- BD
- Becton Dickinson
- Interventional
- Medical Devices
- Medical Technology
- Oncology
- Surgery
- Urology
- Vascular
- Fortune 1000
apis: []
common:
- type: DomainSecurity
  url: security/cr-bard-domain-security.yml
- type: Security
  url: security/cr-bard-vulnerability-disclosure.yml
- type: VulnerabilityDisclosure
  url: security/cr-bard-vulnerability-disclosure.yml
- type: TrustCenter
  url: security/cr-bard-trust-center.yml
- type: Compliance
  url: security/cr-bard-trust-center.yml
- type: LLMsTxt
  url: llms/cr-bard-llms.txt
- type: Website
  url: https://www.bd.com/en-us
- type: ParentCompany
  url: https://www.bd.com/en-us/about-bd/our-company
- type: Solutions
  url: https://www.bd.com/en-us/products-and-solutions/solutions/bd-acute-urology
- type: Careers
  url: https://jobs.bd.com/en/bd-interventional
- type: PressReleases
  url: https://investors.bd.com/news-events/press-releases/detail/352/bd-completes-bard-acquisition-creating-new-global-health-care-leader
- type: Support
  url: https://www.bd.com/en-us/support/contact-us
- type: LinkedIn
  url: https://www.linkedin.com/company/bd1/
- type: PrivacyPolicy
  url: https://www.bd.com/en-us/about-bd/policies/privacy-policy-statement
- type: TermsOfService
  url: https://www.bd.com/en-us/about-bd/policies/terms-of-use
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
x-parent: becton-dickinson
x-relationship: acquisition
x-acquired: 2017
x-enrichment:
  date: '2026-09-07'
  status: minimal
  artifacts_added: 4
  pass: local-v3
x-coverage:
  state: none
  reason: defunct
  detail: C. R. Bard ceased to exist as an operating company when BD completed its acquisition on 2017-12-29; the legacy crbard.com
    domain still resolves but returns a hard 404 from an Azure Application Gateway at the root and at every path probed, and
    no successor developer surface exists under the BD Bard brand.
  evidence:
  - url: https://www.crbard.com/
    status: 404
  - url: https://www.bd.com/en-us/products-and-solutions/products/product-brands/bard
    status: 404
  - url: https://api.bd.com/openapi.json
    status: 502
  - url: https://www.bd.com/.well-known/security.txt
    status: 404
  checked: '2026-09-07'